Synlogic

Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options. The Companys late-stage pipeline is focused on rare metabolic diseases, led by labafenogene marselecobac (SYNB1934), currently being studied as a potential treatment for phenylketonuria (PKU) in Synpheny-3, a global, pivotal Phase 3 study. Additional product candidates address diseases including homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria. This pipeline is fueled by the Synthetic Biotic platform, which applies precision genetic engineering to well-characterized probiotics. This enables Synlogic to create GI-restricted, oral medicines designed to consume or...

Synthetic biology; rare metabolic diseases; drug development; nephrology; rare disease; clinical development; pku; hcu; ibd; homocystinuria; phenylketonuria; synbio; gout; synbio; synthetic biotics; rare disease; and phase 3

Synlogic operates in the Biotechnology research industry.

Synlogic's revenue is $8.00k

Synlogic has 51 - 200 employees.